Trial Outcomes & Findings for Inflammation in Methamphetamine and STIs (IMSTI) (NCT NCT05162391)

NCT ID: NCT05162391

Last Updated: 2026-06-11

Results Overview

Percentage of visits in which there are no detectable methamphetamine metabolites in participant urine samples

Recruitment status

COMPLETED

Study phase

Target enrollment

59 participants

Primary outcome timeframe

8 weeks

Results posted on

2026-06-11

Participant Flow

Participants who were lost to follow-up or withdrawn from the study were replaced to ensure sufficient power in analyses.

Participant milestones

Participant milestones
Measure	Contingency Management All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
Overall Study STARTED	59
Overall Study COMPLETED	30
Overall Study NOT COMPLETED	29

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Inflammation in Methamphetamine and STIs (IMSTI)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Contingency Management n=30 Participants All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
Age, Categorical <=18 years	0 Participants n=20 Participants
Age, Categorical Between 18 and 65 years	30 Participants n=20 Participants
Age, Categorical >=65 years	0 Participants n=20 Participants
Sex: Female, Male Female	0 Participants n=20 Participants
Sex: Female, Male Male	30 Participants n=20 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=20 Participants
Race (NIH/OMB) Asian	0 Participants n=20 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=20 Participants
Race (NIH/OMB) Black or African American	10 Participants n=20 Participants
Race (NIH/OMB) White	8 Participants n=20 Participants
Race (NIH/OMB) More than one race	8 Participants n=20 Participants
Race (NIH/OMB) Unknown or Not Reported	4 Participants n=20 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	13 Participants n=20 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	15 Participants n=20 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	2 Participants n=20 Participants
STI at baseline	7 Participants n=20 Participants

PRIMARY outcome

Timeframe: 8 weeks

Population: All 30 participants included in the analysis were evaluated for the primary outcome. Data is evaluated by total number of study visits completed (n=213). Of the 213 study visits total, 41 visits had no detectable methamphetamine metabolites in participant urine samples.

Percentage of visits in which there are no detectable methamphetamine metabolites in participant urine samples

Outcome measures

Outcome measures
Measure	Contingency Management n=213 Visits All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
Methamphetamine Abstinence	41 Visits

PRIMARY outcome

Timeframe: 8 weeks

Rectal concentrations of IL-6 (pg/mL)

Outcome measures

Outcome measures
Measure	Contingency Management n=30 Participants All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
Rectal Inflammation	1.27 pg/ml Interval 0.07 to 3462.39

Adverse Events

Contingency Management

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Cherie Blair

David Geffen School of Medicine at UCLA

Phone: 3108253807

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place